• Patients with type 1 diabetes are at risk for other autoimmune diseases (ie polyautoimmunity); the most common autoimmune diseases were thyroid disease (20.1%), systemic rheumatic diseases (3.4%), rheumatoid arthritis specifically (2.0%), and gastrointestinal autoimmune diseases (1.4%).
| INTRODUCTION
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic islet β-cells, leading to the need for lifelong insulin-replacement therapy. In addition to microvascular and macrovascular complications, patients with T1D incur the risk of additional autoimmune and immune deficiency diseases (collectively referred to as "autoimmune diseases" or "AID") that further complicate their care and increase their morbidity. Although this phenomenon has been extensively studied in the pediatric population, 1-3 the literature lacks sufficient epidemiological data about AID risk in older adults. The epidemiology of these AID in ethnic minorities has also not been well described. Furthermore, previous studies have focused on endocrine AID, 4, 5 with limited data describing the full spectrum of AID, especially systemic rheumatic diseases, gastrointestinal AID, autoimmune liver disease, immune deficiency disorders, and neurologic diseases.
Patients with one AID are often at increased risk for another. Some AID share common genetic associations. 6 Polyautoimmunity is a term that is used to describe two or more AID occurring concomitantly in one patient. 7, 8 In polyautoimmunity, multiple body systems are often affected, typically with discrete symptoms and disease manifestations. Because of the clustering of endocrine disorders, polyendocrine syndromes have been frequently described, and T1D is a common component of each syndrome. Less well understood are the associations of T1D with other, non-endocrine diseases. To better understand polyautoimmunity in T1D, we undertook a population-level study using the HealthFacts database and analyzed factors affecting the prevalence of additional AIDs in people with T1D across a wide age spectrum.
| METHODS
Study population data were gathered from the HealthFacts (Cerner Corporation, Kansas City, Missouri) national data warehouse, a multifacility, socioeconomically and geographically diverse, Health Insurance Portability and Accountability Act (HIPAA)-compliant, deidentified patient registry. HealthFacts derives data from the electronic medical records of healthcare facilities in which Cerner has a data use agreement. The current University of Missouri -Kansas City installation has data available through 2015 with 63 million unique patients treated in 863 facilities. Access to Cerner HealthFacts is a collaboration between the University of Missouri -Kansas City, Truman Medical Center and Cerner Corporation. This study was approved by the University of Missouri -Kansas City School of Medicine Institutional Research Board as non-human subject research. Study cohort inclusion criteria were adults (age ≥ 18 years) with an International Classification of Diseases (ICD), Ninth Revision (ICD-9) or ICD-10 code specifying a diagnosis of T1D (ie "250.*1" and "E10.**", respectively, where the asterisk denotes a wildcard). Patients with a diagnosis indicating type 2 diabetes were excluded, as were children (age < 18 years) and elderly adults (age > 100 years). For patients included in the study, demographic data (eg age, gender, and race) were gathered, as were all their concomitant diagnosis codes. The diagnosis codes used to identify AID of interest are provided in Supporting Information Table S1 . An expanded list of AID was included to serve as a basis for future research, including diseases such as vitiligo, alopecia, uveitis, and Moyamoya disease, which may have multiple or unclear etiologies.
| Statistical analysis
The prevalence of additional AID according to sex and race was evaluated using Chi-squared or Fisher's exact test when appropriate. The prevalence of AID according to ethnicity was evaluated using Chi-squared tests. Associations between sex and total AID burden were analyzed with the Wilcoxon test. Multivariate logistic regression was used to evaluate the independent effects of sex, race/ethnicity, current age group, and age of T1D diagnosis on the prevalence of an additional AID. Age was categorized into groups (≤29, 30-39, 40-49, 50-59, 60-69, 70-79, and ≥80 years). Two-tailed P < 0.01 was considered significant. Data were analyzed using SAS version 9.4 (SAS Institute, Cary, NC).
| RESULTS
The cross-sectional study cohort comprised 158 865 patients with T1D (mean [AESD] age 51.4 AE 18.9 years; median age 53 years, range 18-90 years; Table 1 ). Of the study cohort, 52.5% were female, 73.3% were White, 21.8% were Black, 2.3% were Hispanic, 1.7% were Asian, and 0.9% were Native American (Table 1) . Interestingly, in this cohort of adults with T1D, women were the majority in all races and ethnicities (51.3% of Caucasians, 55.9% of African Americans, 53.9% of Asians, 51.5% of Hispanics, and 53.8% of Native Americans). Whether mortality is higher in men with T1D is unknown and beyond the scope of the present study. Other demographic information is summarized in Table 1 . The Juvenile Diabetes Research Foundation (JDRF) estimates that there are 1.25 million patients with T1D in the US, with more than 1 million of those being adults. 9 The present study of 158 865 adult patients represents an estimated 16% sample of the adult population with T1D in the US. Table 2 lists all the AID found in the T1D cohort. The most common AID were thyroid disease (20.1%), systemic rheumatic diseases (3.4%; of which rheumatoid arthritis [2.0%] was the most common), and gastrointestinal AID (1.4%). Most of the AID showed significant female Abbreviations: AID, autoimmune disease. Data are given as the mean AE SD or as n (%). P-values are unadjusted. predominance in the T1D population: hypothyroidism (69% female; P < 0.0001), hyperthyroidism (69% female; P < 0.0001), alopecia (79% female; P < 0.0001), celiac disease (64% female; P < 0.0001), rheumatoid arthritis (73% female; P < 0.0001), lupus (82% female; P < 0.0001), and Sjögren syndrome (87% female; P < 0.0001). The only disease that showed male predominance was primary sclerosing cholangitis (55% male; P < 0.01). Of the females with T1D, 25% had one additional AID, 4% had two additional AIDs, and 1% had three additional AIDs. Among males, 14% had one additional AID, 1.7% had two additional AIDs, and 0.2% had three additional AIDs ( Figure 1A ). Females with T1D were more likely than males to have one, two, three, and four or more AID ( Figure 1A ; P < 0.0001).
In the T1D cohort, the prevalence of an additional AID was highest among Caucasians (26%) compared with the other ethnicities (20% of Asians, 18% of Hispanics, 15% of African Americans, and 15% of Native Americans had an additional AID; P < 0.0001; Figure 1B) . The most common AID in every racial group was autoimmune thyroid disease. Asians and Caucasians are at higher risk of systemic rheumatic disease than African Americans, Hispanics, and Native Americans (Table 2 ; P < 0.0001). Celiac disease, ulcerative colitis, Crohn's disease primary biliary cirrhosis, immune deficiency disorders, multiple sclerosis, and myasthenia gravis were more common among Caucasians than other ethnicities. Uveitis was more common among African Americans than other ethnicities. (Note, in Table 2 , race rows not adding up to total prevalence of disease is due to missing data.)
After adjusting for age and race, females with T1D were more likely to have an additional AID (odds ratio [OR] 2.43, 95% confidence interval [CI] 2.37-2.50; P < 0.0001). Race and ethnicity also affected the risk of additional AID. After adjusting for age and gender, African Americans (OR 0.47; 95% CI 0.45-0.49; P < 0.0001), Native Americans (OR 0.49; 95% CI 0.42-0.58; P < 0.0001), Asians (OR 0.68; 95% CI 0.61-0.75; P < 0.0001), and Hispanics (OR 0.63; 95% CI 0.57-0.69; P < 0.0001) were all less likely than Caucasians to develop an additional AID (Table 3) . Native Americans and African Americans had the lowest risk of developing an additional AID (ORs 0.49 and 0.47, respectively).
The likelihood of developing an AID increased with age. Compared with people aged ≤29 years, those aged 30 to 39 years (OR 1.56; 95% CI 1.48-1.65; P < 0.0001), 50 to 59 years (OR 2.22; 95% CI 2.11-2.33; P < 0.0001), 60 to 69 years (OR 2.47; 95% CI 2.35-2.59; P < 0.0001), 70 to 79 years (OR 2.67; 95% CI 2.54-2.81; P < 0.0001), and ≥80 years (OR 2.81; 95% CI 2.65-2.98; P < 0.0001) were more likely to have an additional AID (Table 3; Figure 2 ).
| DISCUSSION
There are three main findings of the present study: (a) additional AID are common in patients with T1D; (b) female sex and older age predict the risk of additional AID; and (c) Native Americans, African Americans, Asians, and Hispanics are at reduced risk of additional AID relative to Caucasians. These findings in ethnic minorities have not been described previously. In addition, our exclusive adult cohort, with a mean age of 51.4 years, provides unique insight into the prevalence of AID in adults with T1D across a broad age spectrum. Although T1D is classically defined as a disease of childhood, recent research finds that the life expectancy for patients with T1D is well into the seventh decade 10 due to advances in technology and therapy for glucose control. Thus, it is imperative for the literature to expand data on these patients as they age so clinicians can adequately assess all comorbidities. With a cohort of 158 865 patients representing a 16% sample of adults with T1D in the US, the present study is currently the largest in the literature investigating polyautoimmunity in adults with T1D. The size and breadth of the HealthFacts database provide sufficient sample size to extrapolate to the entire US population with T1D.
A limitation of this study is the fact that data were sourced from electronic medical records. Diagnosis codes used for billing may not include all AID, such as vitiligo and alopecia, or other diseases not treated by network physicians. Consequently, the present study likely underestimates the prevalence of additional AID in T1D. In addition, ICD-9 and ICD-10 codes have low specificity and often code for multiple diseases, some of which do not have an autoimmune etiology. For example, the ICD-9 11 code 244.9 is defined as "unspecified hypothyroidism," which includes other hypothyroidism-related diagnoses, such as infantile myxedema. However, the most common cause of hypothyroidism in the US is Hashimoto disease, 12 which does have an autoimmune etiology. In addition, we were able to exclude other common causes of hypothyroidism, such as postsurgical or postablative hypothyroidism (because these are coded as 244.0 and 244.1, respectively). As such, due to the drawbacks of using diagnosis codes, these estimates should be used as approximations of true estimates of autoimmunity in T1D. Furthermore, the present study found a slight female predominance in the T1D cohort, whereas the literature has generally reported a slight male predominance in T1D. 13 In every ethnic group in the billing code database, there was a predominance of women with T1D. This was an unexpected finding that lacks a clear explanation. However, it has been shown previously that in the Japanese population there is a higher prevalence of T1D among women than men.
14 Given the older age of the present cohort, life expectancy may play a role in the observation, but sex differences in life expectancy with T1D have not been reported previously. Other limitations of this study are the lack of data on age-matched controls who did not have T1D and the lack of data regarding age of T1D onset. Age of T1D onset is of particular interest because studies have shown that adult-onset T1D has distinct immunologic and clinical characteristics. 15 Future studies should address these gaps in the data. Autoimmune thyroid disease is known to be common in patients with T1D, and the 2018 ADA Standards of Care recommend screening for it. 16 In the present cohort, the prevalence of thyroid disease was 20.1%, which is similar to that reported in previous studies. 4 However, studies that tested thyroid peroxidase or thyroglobulin antibodies found a higher prevalence of thyroid disease in patients with T1D. 1, 17 The present study likely underestimates the prevalence of autoimmune thyroid disease in this population because it relies on billing codes in the absence of antibody data. Excluding postoperative and postablative hypothyroidism may have reduced rates of both hyper-and hypothyroidism. Interestingly, in the present study we found a <1% prevalence of celiac disease, which is lower than expected. The range of prevalence for celiac disease in the T1D population varies from 6% in the Type 1 Clinic Exchange study 18 to 2.9% reported by Triolo et al. 1 Increased screening efforts in younger patients may be responsible for the differences. Underestimation of the true prevalence of celiac disease is likely due to the lack of transglutaminase or gliadin antibody data, as well as reduced symptoms in adults compared with children.
In this study cohort, the prevalence of pernicious anemia was lower than expected. The frequency of pernicious anemia in patients with T1D has been estimated to be in the range 5% to 10%, and has been shown to increase with age. 19, 20 The lower than expected prevalence of this disease in the billing code database likely represents underdiagnosis both in the population and in patients with T1D. The low prevalence of both celiac disease and pernicious anemia in this large cohort suggests that evaluation of anemia in adults with T1D should consider autoimmune causes. In the present study, the prevalence of rheumatoid arthritis was 2.0% in the entire population, and 2.5% in women specifically. This is significantly higher than the prevalence of rheumatoid arthritis in the general US population, which has been estimated to be 0.5% total prevalence and 0.75% in women. 21 This association in our clinical data corroborates studies on genetic predispositions between T1D and rheumatoid arthritis. 22, 23 In patients with T1D, the AID risk across the age spectrum was previously described in the Type 1 Clinic Exchange study by Hughes et al. 18 The present study confirms the increasing risk of concomitant AID with increasing age described by Hughes et al. 18 ; in the present cohort, patients aged ≥80 years had a 2.80-fold increase in odds of having an additional AID relative to patients aged ≤29 years, despite the typically young age at onset of T1D. Not only do older patients have more time to acquire additional diseases, age itself is a risk factor for AID. 24 In light of this evidence, it is possible that there is a loss of immune tolerance with age that precipitates polyautoimmunity in older adults.
In this study, we found a 23.2% prevalence of additional AID in patients with T1D, which is significantly greater than the estimated 4% to 9% prevalence of AID in the general population. 25 Our prevalence rate also exceeds the AID prevalence in T1D cohorts in previous studies. [26] [27] [28] Of particular interest, 30% of women in our cohort experienced an additional AID, underscoring the importance of monitoring for additional AIDs in women with T1D. Compared with the prevalence of other complications of diabetes, the risk of acquiring an additional AID is substantial. For example, the prevalence of diabetic retinopathy has been estimated to be 28.5%, 29 and the prevalence of diabetic peripheral neuropathy has been estimated to be at least 20%. 30 Notably, the prevalence of all these diseases and diabetes complications increases with age, which adds to both treatment complexity and morbidity in older patients with T1D. People with T1D are at increased risk of both endocrine and non-endocrine AID, suggesting that loss of immune tolerance may not be unique to endocrine diseases. The risk of autoimmunity should be considered as an additional complication of T1D. Polyautoimmunity presents a significant burden on patient quality of life as well as on healthcare systems. 31 In addition, it has been established that chronic inflammation increases the risk of cardiovascular disease. 32, 33 Furthermore, many of these diseases and even antibodies that occur in polyautoimmunity put patients at risk for complications of pregnancy. 34 The increase in AID risk with age in patients with either polyendocrine syndromes or polyautoimmunity is a finding that needs additional verification and exploration. Although T1D is typically diagnosed at younger ages, it may be a risk factor or marker for loss of immune tolerance or epigenetic changes with age. Future studies should consider age, sex, and ethnicity in the study of single or multiple AID. Clinicians treating T1D patients should be aware of the risks for additional AID, particularly in older Caucasian women with T1D, and for AID that may present with subtle or nonspecific symptoms, such as celiac disease or the early manifestations of systemic rheumatic disease. Finally, our results add further evidence in favor of recognizing the common features of AID (ie the autoimmune tautology). 35 
